Effects and mechanism of downregulation of COX‑2 expression by RNA interference on proliferation and apoptosis of human breast cancer MCF‑7 cells

Han,Hui; Yang,Sheng; Lin,Shun‑Guo; Xu,Chun‑Sen; Han,Zhong‑Hua

doi:10.3892/mmr.2014.2659

Effects and mechanism of downregulation of COX‑2 expression by RNA interference on proliferation and apoptosis of human breast cancer MCF‑7 cells

Authors:
- Hui Han
- Sheng Yang
- Shun‑Guo Lin
- Chun‑Sen Xu
- Zhong‑Hua Han
View Affiliations

Affiliations: Department of Breast Surgery, The Union Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Medical Oncology, The Union Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
Published online on: October 15, 2014 https://doi.org/10.3892/mmr.2014.2659
Pages: 3092-3098

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of RNA interference with prostaglandin-endoperoxide synthase 2 (COX‑2) gene on the proliferation and apoptosis of breast cancer MCF‑7 cells, as well as the underlying mechanism. The present study constructed the eukaryotic expression vector of the targeted COX‑2 gene, transfected the MCF‑7 cells and screened the stably expressed clone. Changes in the COX‑2 gene expression in breast cancer MCF‑7 cells prior to and following transfection were examined; the proliferation and apoptosis of MCF‑7 cells were analyzed. Furthermore, changes in the protein levels of survivin, B-cell lymphoma 2 (Bcl‑2) and Bcl-2-associated X (Bax) genes were detected. RNA interference mediated by a lentiviral expression vector significantly decreased the protein expression levels of the COX‑2 gene, and therefore, the proliferation and growth of breast cancer MCF‑7 cells was significantly suppressed and the apoptotic rate increased. Of note, the mRNA and protein expression levels of survivin and Bcl‑2 decreased, while those of Bax increased following COX-2 silencing. RNA interference markedly deactivated the COX‑2 gene, suppressed the proliferation of breast cancer MCF‑7 cells, and, to a certain extent, enhanced the induced spontaneous apoptosis, which is regulated by the Bax gene. These results provided evidence for the potential applications of RNA interference of the targeted COX‑2 gene in gene therapy for the treatment of breast cancer.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Lazzeroni M and Decensi A: Breast cancer prevention by antihormones and other drugs: where do we stand? Hematol Oncol Clin North Am. 27:657–672. 2013. View Article : Google Scholar
3	Singel SM, Cornelius C, Batten K, et al: A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin Cancer Res. 19:2061–2070. 2013. View Article : Google Scholar
4	Zheng WY, Kang YY, Li LF, et al: Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells. Drug Discov Ther. 5:293–238. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ashihara E: RNA interference for cancer therapies. Gan To Kagaku Ryoho. 37:2033–2041. 2010.PubMed/NCBI
6	Liu JL, Wei W, Tang W, et al: Silencing of lysyl oxidase gene expression by RNA interference suppresses metastasis of breast cancer. Asian Pac J Cancer Prev. 13:3507–3511. 2012. View Article : Google Scholar : PubMed/NCBI
7	Timoshenko AV, Chakraborty C, Wagner GF, et al: COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer. 4:1154–1163. 2006. View Article : Google Scholar : PubMed/NCBI
8	Dhakal HP, Naume B, Synnestvedt M, et al: Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol Histopathol. 27:1315–1325. 2012.PubMed/NCBI
9	Troisi R, Altantsetseg D, Davaasambuu G, et al: Breast cancer incidence in Mongolia. Cancer Causes Control. 23:1047–1053. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chuang E, Paul C, Flam A, et al: Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health. 14:754–758. 2012. View Article : Google Scholar : PubMed/NCBI
11	Engebraaten O, Moen Vollan HK and Børresen-Dale AL: Triple-Negative Breast Cancer and the Need for New Therapeutic Targets. Am J Pathol. pii: S0002–S9440, 00461–00466. 2013. View Article : Google Scholar : PubMed/NCBI
12	De Los Santos JF, Cantor A, Amos KD, et al: Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 119:1776–1183. 2013.
13	Brim RL and Pearson SD: The use and reporting of patient-reported outcomes in phase III breast cancer trials. Clin Trials. 10:243–249. 2013. View Article : Google Scholar : PubMed/NCBI
14	Arthur DW, Vicini FA, Todor DA, et al: Contura Multi-Lumen Balloon breast brachytherapy catheter: comparative dosimetric findings of a phase 4 trial. Int J Radiat Oncol Biol Phys. 86:264–269. 2013. View Article : Google Scholar
15	Holmes MD, Chen WY, Schnitt SJ, et al: COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 130:657–662. 2011. View Article : Google Scholar : PubMed/NCBI
16	Singh AK, Parshad R, Pasi S, et al: Prognostic significance of cyclooxygenase-2 and response to chemotherapy in invasive ductal breast carcinoma patients by real time surface plasmon resonance analysis. DNA Cell Biol. 30:801–807. 2011. View Article : Google Scholar
17	Bennett A, Berstock DA, Carroll MA, et al: Breast cncer, its recurrence, and patient survival in relation to tumor prostaglandins. Adv Prostaglandin Thromboxane Leukot Res. 12:299–302. 1983.PubMed/NCBI
18	Spizzo G, Gastl G, Wolf D, et al: Correlation of COX-2 and Ep-CAM over expression in human invasive breast cancer and its impact on survival. Br J Cancer. 88:574–578. 2003. View Article : Google Scholar : PubMed/NCBI
19	Denkert C, Winzer KJ and Hauptmann S: Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer. 4:428–433. 2004. View Article : Google Scholar : PubMed/NCBI
20	Dhakal HP, Naume B, Synnestvedt M, et al: Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol Histopathol. 27:1315–1325. 2012.PubMed/NCBI
21	Ristimäki A, Sivula A, Lundin J, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
22	Oliveira VM, Piato S and Silva MA: Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat. 95:235–241. 2006. View Article : Google Scholar
23	Takafuji VA, Evans A, Lynch KR and Roche JK: PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer. Prostaglandins Leukot Essent Fatty Acids. 66:71–81. 2002. View Article : Google Scholar : PubMed/NCBI
24	Khor LY, Bae K, Pollack A, et al: COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 tria1. Lancet Oncol. 8:912–920. 2007. View Article : Google Scholar : PubMed/NCBI
25	Pazhang Y, Ahmadian S, Javadifar N, et al: COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line. Tumour Biol. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
26	Singh B and Lucci A: Role of cyclooxygenase-2 in breast cancer. J Surg Res. 108:173–179. 2002. View Article : Google Scholar : PubMed/NCBI
27	Sivula A, Talvensaari-Mattila A, Lundin J, et al: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 89:215–220. 2005. View Article : Google Scholar : PubMed/NCBI
28	Uefuji K, Ichikura T and Mochizuki H: Cyclooxygenase-2 expression is related to prostagland in biosynthesis and angiogenes is in gastric cancer. Clin Cancer Res. 6:135–138. 2000.PubMed/NCBI
29	Surowiak P, Materna V, Matkowski R, et al: Relationship between the expression of cyclooxygenase-2 and MDR1/P2glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 7:R862–R870. 2005. View Article : Google Scholar : PubMed/NCBI
30	Kundu N, Smyth MJ, Samsel L, et al: Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat. 76:57–64. 2002. View Article : Google Scholar : PubMed/NCBI
31	Salhab M, Singh-Ranger G, Mokbel R, et al: Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol. 96:424–8. 2007. View Article : Google Scholar : PubMed/NCBI
32	Basu GD, Pathangey LB, Tinder TL, et al: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res. 2:632–642. 2004.PubMed/NCBI
33	O’Mahony CA, Beauchamp RD, Albo D, et al: Cyclooxygenase 2 alters transforming growth factor β1 response during intestinal tumorigenesis. Surgery. 126:364–370. 1999.
34	Orlov SN, Thorin-Trescases N, Dulin NO, et al: Activation of cAMP signaling transiently inhibits apoptosis in vascular smooth muscle cells in a site upstream of caspase-3. Cell Death Differ. 6:661–672. 1999. View Article : Google Scholar
35	Cao Y, Pearman AT, Zimmerman GA, et al: Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA. 7:11280–1128. 2000. View Article : Google Scholar : PubMed/NCBI
36	Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 190:279–286. 2002. View Article : Google Scholar : PubMed/NCBI
37	Yousif S, Chaves C, Potin S, et al: Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation. J Neurochem. 123:491–503. 2012. View Article : Google Scholar : PubMed/NCBI
38	Jana D, Sarkar DK, Maji A, et al: Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer? J Indian Med Assoc. 110:429–433. 2012.